Kinnate Biopharma’s KIN-2787 Inhibitor Receives Fast Track FDA Designation for Melanoma Treatment
September 22, 2022
Trending News 🌧️
Kinnate Biopharma Intrinsic Value – Kinnate Biopharma($NASDAQ:KNTE)’s clinical-stage oncology inhibitor, KIN-2787, has received Fast Track FDA designation for the treatment of melanoma. This is the most serious type of skin cancer, and the Fast Track designation will help to speed up the development and review process for KIN-2787.
The exact indication for KIN-2787 is for the treatment of patients with BRAF Class II or III alteration-positive and/or NRAS mutation-positive stage IIb to IV malignant melanoma that is metastatic or unresectable. This will hopefully provide a much needed treatment option for patients with this difficult to treat disease.
Share Price
While the news was generally well-received, some investors are concerned about the company’s ability to successfully commercialize the drug. The drug has shown promising results in early clinical trials, leading to the FDA’s Fast Track designation. This designation will allow Kinnate to receive additional feedback from the FDA during the drug development process and could potentially expedite the approval process. While the news is positive, some investors are concerned about the company’s ability to commercialize the drug given the competitive landscape.
There are already several approved melanoma treatments on the market and several more in development. Kinnate will need to prove that KIN-2787 is superior to existing treatments in order to be successful.
VI Analysis – Kinnate Biopharma Intrinsic Value Calculator
Kinnate Biopharma’s fundamentals reflect the company’s long-term potential, and the VI app makes it easy to analyze these fundamentals. The fair value of a Kinnate Biopharma share is around $16.4, based on the VI Line. However, the stock is currently trading at $12.1, which represents a 26% discount to its fair value.
Summary
This news has caused sentiment around the company to become mostly negative, as investors are worried about the company’s ability to successfully bring this treatment to market. While the Fast Track FDA Designation is a positive step, there are still many hurdles that Kinnate Biopharma will need to overcome before KIN-2787 is approved for use in the United States.
